Related Experiment Video
Updated: Nov 17, 2025

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
Published on: July 3, 2025
TFAP2A-induced SLC2A1-AS1 promotes cancer cell proliferation
Yuanbo Cui1, Chunyan Zhang2, Shanshan Ma1
1School of Life Sciences, Zhengzhou University, Zhengzhou450001, China.
The study reveals that the long non-coding RNA (lncRNA) SLC2A1-AS1 acts as an oncogene in lung adenocarcinoma (LUAD). It promotes cancer cell proliferation by interacting with miR-508-5p and is regulated by TFAP2A.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Long non-coding RNAs (lncRNAs) play a role in human cancers, including lung adenocarcinoma (LUAD).
- The specific role and expression of the novel lncRNA SLC2A1-AS1 in cancer are not well understood.
- Previous reports indicate SLC2A1-AS1 is highly expressed in various cancer types.
Purpose of the Study:
- To investigate the expression and function of lncRNA SLC2A1-AS1 in LUAD.
- To elucidate the molecular mechanisms underlying SLC2A1-AS1's role in LUAD progression.
- To explore the relationship between SLC2A1-AS1, miR-508-5p, and TFAP2A in cancer.
Main Methods:
- Quantitative real-time PCR to assess SLC2A1-AS1 and TFAP2A expression.
- Cell proliferation assays (in vitro) to evaluate the functional impact of SLC2A1-AS1.
- RNA immunoprecipitation and luciferase reporter assays to confirm molecular interactions.
- Bioinformatic analysis to correlate expression with patient survival.
Main Results:
- SLC2A1-AS1 was significantly over-expressed in LUAD tissues and correlated with poorer overall survival (OS).
- Knockdown of SLC2A1-AS1 inhibited LUAD cell proliferation, while its overexpression accelerated it.
- SLC2A1-AS1 directly targets and downregulates miR-508-5p, partially mediating its oncogenic effect.
- TFAP2A, highly expressed in LUAD, positively regulates SLC2A1-AS1 transcription and predicts worse OS.
- TFAP2A-induced SLC2A1-AS1 promotes proliferation in LUAD, lung squamous cell carcinoma (LUSC), and pancreatic adenocarcinoma (PAAD).
Conclusions:
- The TFAP2A-SLC2A1-AS1 axis functions as an oncogenic pathway driving cancer cell proliferation.
- SLC2A1-AS1 is a potential therapeutic target in LUAD and other cancers.
- Understanding this regulatory network provides insights into cancer development and progression.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Cell Migration through Invadopodia
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancers Originate from Somatic Mutations in a Single Cell
Abnormal Proliferation

